天竺雾化液通过TRPV1通路和TLR2-MyD88-NF-κB通路治疗慢性咽炎  

Tianzhu atomized solution treats rats with chronic pharyngitis through the TRPV1 and TLR2-MyD88-NF-κB pathways

作　　者：洪冬冬 刘沁东 李丹[1] 杨龙[1] 杨素娟[1] 郭绍举[1] 刘霞[1] 胡镇 李贞贞[1] 赵元 于枫[1] 刘元献[1] HONG Dongdong;LIU Qindong;LI Dan;YANG Long;YANG Sujuan;GUO Shaoju;LIU Xia;HU Zhen;LI Zhenzhen;ZHAO Yuan;YU Feng;LIU Yuanxian(Shenzhen Traditional Chinese Medicine Hospital,Shenzhen,Guangdong,518033,China)

机构地区：[1]广东深圳市中医院,518033

出　　处：《中国中西医结合耳鼻咽喉科杂志》2024年第6期401-408,416,共9页Chinese Journal of Otorhinolaryngology in Integrative Medicine

基　　金：深圳市自然面上项目(JCYJ20210324111205016);深圳市‘医疗三名工程’项目资助(SZZYSM202311005)。

摘　　要：目的本研究旨在探讨天竺雾化液(TZWHY)在治疗慢性咽炎(Chronic Pharyngitis,CP)中的分子机制。我们采用大鼠体内实验来揭示这一机制。方法本研究通过建立细菌性慢性咽炎模型,使用不同剂量的TZWHY进行雾化处理,评估其抗炎作用。使用LC-MS对药物成分进行质谱分析,采用ELISA测定血清中IL-6、IL-1β和TNF-α的水平,实时PCR检测TLR2 mRNA表达,Western Blot分析MyD88、NF-κB p-p65和TRPV1蛋白表达。结果慢性咽炎实验模型显示TZWHY可有效改善大鼠症状,ELISA结果显示TZWHY治疗可有效降低血清中IL-6、IL-1β和TNF-α的升高,WB及qPCR结果显示TZWHY可降低咽部黏膜组织中NF-κB P65、MyD88、TLR-2和TRPV1的升高。结论本研究通过大鼠实验研究,探讨并确认了TZWHY治疗CP的作用机制。研究结果表明,TZWHY可能通过调节TRPV1通路和TLR2-MyD88-NF-κB通路治疗慢性咽炎。Objective This study aims to investigate the molecular mechanism of Tianzhu Atomized Solution(TZWHY)in treating chronic pharyngitis(CP).We used an in vivo rat model to elucidate this mechanism.Methods A bacterial chronic pharyngitis model was established,and different doses of TZWHY were administered via aerosol treatment to evaluate its anti-inflammatory effects.LC-MS was used for component analysis of the medication.ELISA was employed to measure serum levels of IL-6,IL-1β,and TNF-α,real-time PCR was used to detect TLR2 mRNA expression,and Western blot was used to analyze the expression of MyD88,NF-κB p-p65,and TRPV1 proteins.Results The CP model showed that TZWHY effectively alleviated symptoms in rats.ELISA results indicated that TZWHY significantly reduced the elevated serum levels of IL-6,IL-1β,and TNF-α.Western blot and qPCR results demonstrated that TZWHY decreased the elevated levels of NF-κB p65,MyD88,TLR2,and TRPV1 in pharyngeal mucosal tissues.Conclusion This study explored and confirmed the therapeutic mechanism of TZWHY in treating CP through rat experiments.The results suggest that TZWHY may treat chronic pharyngitis by regulating the TRPV1 pathway and the TLR2-MyD88-NF-κB pathway.

关 键 词：慢性咽炎 抗生素耐药性 NF-ΚB TRPV1 

分 类 号：R285.5[医药卫生—中药学]